Trial Profile

A Phase II Clinical Study of SHR3680 Combined With Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Rezvilutamide (Primary)
Indications Carcinoma; Neuroendocrine carcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

04 Jun 2024 Results (As of Aug 31, 2023, n=36) assessing the safety, PK, and preliminary efficacy of addition of REZ (a novel androgen receptor inhibitor) to DOC in chemo-naive mCRPC patients presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
19 Feb 2021 Status changed from not yet recruiting to recruiting.
29 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com